Nyagwange did his PhD jointly between Wageningen University, Netherlands and International Livestock Research Institute, Kenya. During his PhD he identified novel Theileria parva vaccine candidate antigens for development of a subunit vaccine for controlling a cattle disease called East Coast fever. In 2018 he started a joint postdoc between KWTRP and Pirbright Institute. While at Pirbright he actively participated in setting up a single B-cell sequencing protocol to fast tract monoclonal antibody discovery. At KWTRP he works with arboviruses including Rift-Valley fever, Dengue and Chikungunya. He actively participated in measuring if there was vaccine shedding following vaccination with a Rift Valley fever vaccine called ChAdOx1-RVF. His work with Dengue and Chikungunya includes identification of lead antigens /epitopes, designing constructs in silico and laboratory testing. Recently, he actively contributed to the development of ELISA and pseudo-neutralization assay for SARS-CoV-2 and is interested in investigating the presence and role of pre-existing antibodies to coronaviruses.